Optimization techniques for novel c-Met kinase inhibitors

References

• Heymach J, Krilov L, Alberg A, et al. Clinical cancer advances 2018: annual report on progress against cancer from the American society of clinical oncology. J clin oncol. 2018;36(10):1020–1044.
   PubMed Web of Science ®Google Scholar
• Mohar A, Reynoso N, Meneses A. Abstract IA04: developing a national plan for cancer prevention and control; balancing unmet needs and addressing global disparities. Cancer Epidemiol Biomarkers Prev. 2017;26(2 Supplement):IA04–IA04.
   Web of Science ®Google Scholar
• Low PS, Singhal S, Srinivasarao M. Fluorescence-guided surgery of cancer: applications, tools and perspectives. Curr Opin Chem Biol. 2018;45:64–72.
   PubMed Web of Science ®Google Scholar
• Vaidya JS, Bulsara M, Wenz F, et al. Targeted radiotherapy for early breast cancer. Lancet. 2018;391(10115):26–27.
   PubMed Web of Science ®Google Scholar
• Hartner L. Chemotherapy for oral cancer. Dent Clin North Am. 2018;62(1):87–97.
   PubMedGoogle Scholar
• Fakih M. Biological therapy in colorectal cancer in the era of sidedness. Oncol Times. 2017;39(10):1–9.
   Google Scholar
• Lin YE, Jia Y, Ke JI, et al. Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis. Oncol Lett. 2015;10(3):1240–1250.
   PubMed Web of Science ®Google Scholar
• Bhullar KS, Lagarón NO, Mcgowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48.
   PubMedGoogle Scholar
• Basilico C, Arnesano A, Galluzzo M, et al. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem. 2008;283(30):21267–21277.
   PubMed Web of Science ®Google Scholar
• Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802–804.
   PubMed Web of Science ®Google Scholar
• Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22(4):309–325.
   PubMed Web of Science ®Google Scholar
• Okuma HS, Kondo S. Trends in the development of MET inhibitors for hepatocellular carcinoma. Future Oncol. 2016;12(10):1275–1286.
   PubMed Web of Science ®Google Scholar
• Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010;16(1):37–45.
   PubMed Web of Science ®Google Scholar
• Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3(1 Suppl):S7–S19.
   PubMedGoogle Scholar
• Yamamoto S, Tsuda H, Miyai K, et al. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol. 2011;24(8):1146–1155.
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Mills GB, Gonzalezangulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(26):3287–3296.
   PubMed Web of Science ®Google Scholar
• Salgia R. MET in lung cancer: biomarker selection based on scientific rationale. Mol Cancer Ther. 2017;16(4):555–565.
   PubMed Web of Science ®Google Scholar
• FDA approves crizotinib with companion diagnostic for a type of late-stage lung cancer. Drug Topics. 2011. [cited 2018 Apr 21]. Available at: http://www.drugtopics.com/chains-business/fda-approves-crizotinib-companion-diagnostic-type-late-stage-lung-cancer
   Google Scholar
• Malik SM, Maher VE, Bijwaard KE, et al. U.S. food and drug administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res. 2014;20(8):2029–2034.
   PubMed Web of Science ®Google Scholar
• Traynor K. Cabozantinib approved for advanced medullary thyroid cancer. Am J Health Syst Pharm. 2013;70(2):88.
   Web of Science ®Google Scholar
• Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J clin oncol. 2013;31(4):412–419.
   PubMed Web of Science ®Google Scholar
• Yavuz S, Apolo AB, Kummar S, et al. Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. Thyroid Off J Am Thyroid Assoc. 2014;24(8):1223–1231.
   PubMed Web of Science ®Google Scholar
• Daud A, Kluger HM, Kurzrock R, et al. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017;116(4):432–440.
   PubMed Web of Science ®Google Scholar
• Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016;17(12):1653–1660.
   PubMed Web of Science ®Google Scholar
• Verslype C, Cohn AL, Kelley RK, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase 2 randomized discontinuation trial (RDT). J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(4_suppl):261.
   Web of Science ®Google Scholar
• Choueiri TK, Pal SK, Mcdermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(8):1603–1608.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Assenat E, Peck-Radosavljevic M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19(5):682–693.
   PubMed Web of Science ®Google Scholar
• Azuma K, Hirashima T, Yamamoto N, et al. Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. Esmo Open. 2016;1(4):e000063.
   PubMed Web of Science ®Google Scholar
• Eng C, Bessudo A, Hart LL, et al. A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. Int J Cancer. 2016;139(1):177–186.
   PubMed Web of Science ®Google Scholar
• Baljevic M, Zaman S, Baladandayuthapani V, et al. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017;96(6):977–985.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Bozzarelli S, Cordio S, et al. PD-028Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC). Ann Oncol. 2017;28(suppl_3):11.
   Google Scholar
• Geller JI, Perentesis JP, Liu X, et al. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: a children’s oncology group study phase 1 and pilot consortium trial (ADVL1111). Pediatr Blood Cancer. 2017;64(11):e26565.
   Web of Science ®Google Scholar
• Yau TC, Lencioni R, Sukeepaisarnjaroen W, et al. A phase I/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2017;23(10):2405–2413.
   PubMed Web of Science ®Google Scholar
• Chia SK, Ellard SL, Mates M, et al. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast Cancer Res. 2017;19(1):54.
   PubMedGoogle Scholar
• Leighl NB, Tsao MS, Liu G, et al. A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget. 2017;8(41):69651–69662.
   PubMedGoogle Scholar
• Shapiro GI, Mccallum S, Adams LM, et al. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs. 2015;33(6):1292.
   PubMed Web of Science ®Google Scholar
• Rayson D, Lupichuk S, Potvin K, et al. Canadian cancer trials group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Res Treat. 2016;157(1):109–116.
   PubMed Web of Science ®Google Scholar
• Parikh PK, Ghate MD. Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Eur J Med Chem. 2017;143:1103–1138.
   PubMed Web of Science ®Google Scholar
• Klebe G. Comparative molecular similarity indices analysis: coMSIA. Perspect Drug Discovery Des. 1998;12–14(10):87–104.
   Google Scholar
• Kubinyi H. Comparative molecular field analysis (CoMFA). Encycl Comput Chem. 1998;1:448–460.
   Google Scholar
• Shah F, Gut J, Legac J, et al. Computer-aided drug design of falcipain inhibitors: virtual screening, structure-activity relationships, hydration site thermodynamics, and reactivity analysis. J Chem Inf Model. 2012;52(3):696–710.
   PubMed Web of Science ®Google Scholar
• Hsu YC, Shiao HY, Ke YY, et al. Abstract 2530: optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML. Cancer Res. 2014;74(19 Supplement):2530.
   Web of Science ®Google Scholar
• Kakarla P, Inupakutika M, Devireddy AR, et al. 3D-QSAR and contour map analysis of tariquidar analogues as multidrug resistance protein-1 (MRP1) inhibitors. Int J Pharm Sci Res. 2016;7(2):554–572.
   PubMed Web of Science ®Google Scholar
• Wang JL, Cheng LP, Wang TC, et al. Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques. J Mol Graph Model. 2017;72:178–186.
   PubMed Web of Science ®Google Scholar
• Patel S, Patel B, Bhatt H. 3D-QSAR studies on 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4- carboxamide derivatives as HIV-1 integrase inhibitors. J Taiwan Inst Chem Eng. 2016;59:61–68.
   Web of Science ®Google Scholar
• Li W, Si H, Li Y, et al. 3D-QSAR and molecular docking studies on designing inhibitors of the hepatitis C virus NS5B polymerase. J Mol Struct. 2016;1117:227–239.
   Web of Science ®Google Scholar
• Aouidate A, Ghaleb A, Ghamali M, et al. Furanone derivatives as new inhibitors of CDC7 kinase: development of structure activity relationship model using 3D QSAR, molecular docking, and in silico ADMET. Struct Chem. 2018;29(4):1031–1043.
   Web of Science ®Google Scholar
• Gao H. Predicting tyrosinase inhibition by 3D QSAR pharmacophore models and designing potential tyrosinase inhibitors from traditional Chinese medicine database. Phytomedicine. 2018;38:145–157.
   PubMed Web of Science ®Google Scholar
• Aouidate A, Ghaleb A, Ghamali M, et al. Computer aided drug design based on 3D-QSAR and molecular docking studies of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amine derivatives as PIM2 inhibitors: a proposal to chemists. Silico Pharmacol. 2018;6(1):1–14.
   PubMedGoogle Scholar
• Singh U, Gangwal RP, Dhoke GV, et al. 3D-QSAR and molecular docking analysis of (4-piperidinyl)-piperazines as acetyl-CoA carboxylases inhibitors. Arabian J Chem. 2017;10:S617–S626.
   Web of Science ®Google Scholar
• Tang Q, Zhao Y, Du X, et al. Design, synthesis, and structure–activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents. Eur J Med Chem. 2013;69(69C):77–89.
   PubMedGoogle Scholar
• Qi B, Tao H, Wu D, et al. Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors. Arch Pharm (Weinheim). 2013;346(8):596–609.
   PubMed Web of Science ®Google Scholar
• Li S, Zhao Y, Wang K, et al. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors. Bioorg Med Chem. 2013;21(11):2843–2855.
   PubMed Web of Science ®Google Scholar
• Qi B, Mi B, Zhai X, et al. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c -Met kinase inhibitors. Bioorg Med Chem. 2013;21(17):5246–5260.
   PubMed Web of Science ®Google Scholar
• Xin Z, Bao G, Wang L, et al. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors. Bioorg Med Chem. 2016;24(6):1331–1345.
   PubMed Web of Science ®Google Scholar
• Liu J, Nie M, Wang Y, et al. Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors. Eur J Med Chem. 2016;123:431–446.
   PubMed Web of Science ®Google Scholar
• Liu J, Yang D, Yang X, et al. Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors. Bioorg Med Chem. 2017;25(16):4475–4486.
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang N, Zhao S, et al. Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives as selective c-Met inhibitors. Bioorg Med Chem. 2016;25(3):886–896.
   PubMed Web of Science ®Google Scholar
• Zhao S, Yu Z, Zhou H, et al. Synthesis and biological evaluation of 4-(2-fluorophenoxy)-3,3′-bipyridine derivatives as potential c-met inhibitors. Eur J Med Chem. 2016;120:37–50.
   PubMed Web of Science ®Google Scholar
• Zhang W, Ai J, Shi D, et al. Discovery of novel type II c-Met inhibitors based on BMS-777607. Eur J Med Chem. 2014;80(80):254–266.
   PubMedGoogle Scholar
• Cui H, Peng X, Liu J, et al. Design, synthesis and biological evaluation of c-Met kinase inhibitors bearing 2-oxo-1,2-dihydroquinoline scaffold. Bioorg Med Chem Lett. 2016;26(18):4483–4486.
   PubMed Web of Science ®Google Scholar
• Zhang W, Ai J, Shi D, et al. Discovery of novel c-Met inhibitors bearing a 3-carboxyl piperidin-2-one scaffold. Molecules. 2014;19(2):2655–2673.
   PubMed Web of Science ®Google Scholar
• Xing W, Ai J, Jin S, et al. Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis. Eur J Med Chem. 2015;95:302–312.
   PubMed Web of Science ®Google Scholar
• Liu Y, Jin S, Peng X, et al. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase. Eur J Med Chem. 2016;108:322–333.
   PubMed Web of Science ®Google Scholar
• Lu D, Yan J, Wang L, et al. Design, Synthesis, and biological evaluation of the first c-Met/HDAC inhibitors based on pyridazinone derivatives. ACS Med Chem Lett. 2017;8(8):830–834.
   PubMed Web of Science ®Google Scholar
• Dong L, Shen A, Yang L, et al. Design and synthesis of novel benzo[d]oxazol-2(3H)-one derivatives bearing 7-substituted-4-enthoxyquinoline moieties as c-Met kinase inhibitors. Eur J Med Chem. 2016;115:191–200.
   PubMed Web of Science ®Google Scholar
• Kang ST, Kim EY, Archary R, et al. Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors. Bioorg Med Chem Lett. 2014;24(21):5093–5097.
   PubMed Web of Science ®Google Scholar
• Kim EY, Kang ST, Jung H, et al. Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors. Arch Pharm Res. 2016;39(4):453–464.
   PubMed Web of Science ®Google Scholar
• Chi HP, Cho SY, Ha JD, et al. Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells. Bmc Cancer. 2016;16(1):35.
   PubMedGoogle Scholar
• Kim KS, Zhang L, Schmidt R, et al. Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem. 2008;51(17):5330–5341.
   PubMed Web of Science ®Google Scholar
• Zhu W, Wang W, Shan X, et al. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1 H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors. Bioorg Med Chem. 2016;24(8):1749–1756.
   PubMed Web of Science ®Google Scholar
• Tang Q, Wang L, Tu Y, et al. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors. Bioorg Med Chem Lett. 2016;26(7):1680–1684.
   PubMed Web of Science ®Google Scholar
• Wang LX, Liu X, Xu S, et al. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors. Eur J Med Chem. 2017;141:538–551.
   PubMed Web of Science ®Google Scholar
• Tang Q, Wang L, Duan Y, et al. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors. Eur J Med Chem. 2017;133:97–106.
   PubMed Web of Science ®Google Scholar
• Tang Q, Duan Y, Wang L, et al. Synthesis and antiproliferative activity of pyrrolo[2,3-b]pyridine derivatives bearing the 1,8-naphthyridin-2-one moiety. Eur J Med Chem. 2017;143:266–275.
   PubMed Web of Science ®Google Scholar
• Wang L, Xu S, Liu X, et al. Discovery of thinopyrimidine-triazole conjugates as c-Met targeting and apoptosis inducing agents. Bioorg Chem. 2018;77:370–380.
   PubMed Web of Science ®Google Scholar
• Wang L, Xu S, Chen X, et al. Synthesis and bioevaluation study of novel N-methylpicolinamide and thienopyrimidine derivatives as selectivity c-Met kinase inhibitors. Bioorg Med Chem. 2017;26(1):245–256.
   PubMed Web of Science ®Google Scholar
• Boezio AA, Berry L, Albrecht BK, et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6307–6312.
   PubMed Web of Science ®Google Scholar
• Ryu JW, Han SY, Yun JI, et al. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors. Bioorg Med Chem Lett. 2011;21(23):7185–7188.
   PubMed Web of Science ®Google Scholar
• Park BH, Jung KH, Yun SM, et al. KRC-327, a selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity. Cancer Lett. 2013;331(2):158–166.
   PubMed Web of Science ®Google Scholar
• Cho SY, Han SY, Ha JD, et al. Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors. Bioorg Med Chem Lett. 2010;20(14):4223–4227.
   PubMed Web of Science ®Google Scholar
• Lee J, Han SY, Jung H, et al. Synthesis and structure-activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors. Bioorg Med Chem Lett. 2012;22(12):4044–4048.
   PubMed Web of Science ®Google Scholar
• Bode CM, Boezio AA, Albrecht BK, et al. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors. Bioorg Med Chem Lett. 2012;22(12):4089–4093.
   PubMed Web of Science ®Google Scholar
• Chen F, Wang Y, Ai J, et al. O-Linked triazolotriazines: potent and selective c-Met inhibitors. Chemmedchem. 2012;7(7):1276–1285.
   PubMed Web of Science ®Google Scholar
• Zhan Z, Peng X, Liu Q, et al. Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor. Eur J Med Chem. 2016;116:239–251.
   PubMed Web of Science ®Google Scholar
• Ma Y, Sun G, Chen D, et al. Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors. J Med Chem. 2015;58(5):2513–2529.
   PubMed Web of Science ®Google Scholar
• Zhao F, Zhang J, Zhang L, et al. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase. Bioorg Med Chem. 2016;24(18):4281–4290.
   PubMed Web of Science ®Google Scholar
• Zhao F, Zhang LD, Hao Y, et al. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization. Eur J Med Chem. 2017;134:147–158.
   PubMed Web of Science ®Google Scholar
• Engstrom L, Aranda R, Lee M, et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models. Clin Cancer Res. 2017;23(21):6661–6672.
   PubMed Web of Science ®Google Scholar
• Prins PA, Al-Hajeili MR, Kim KS, et al. MET inhibition and merestinib (LY-2801653) for cancer treatment. Drugs Future. 2016;41(10):607–615.
   Web of Science ®Google Scholar
• Patwardhan PP, Ivy KS, Musi E, et al. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget. 2016;7(4):4093–4109.
   PubMedGoogle Scholar
• Xi N, Zhang Y, Wang Z, et al. Abstract 1755: CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth. Cancer Res. 2014;74(19 Supplement):1755.
   Web of Science ®Google Scholar
• Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev Drug Discov. 2011;10(12):897–898.
   PubMed Web of Science ®Google Scholar
• Burbridge MF, Bossard CJ, Saunier C, et al. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol Cancer Ther. 2013;12(9):1749–1762.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Xue J. Paclitaxel inhibits breast cancer metastasis via suppression of Aurora kinase-mediated cofilin-1 activity. Exp Ther Med. 2018;15(2):1269–1276.
   PubMed Web of Science ®Google Scholar
• Li GQ, Guo XB, Fu LC, et al. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans R Soc Trop Med Hyg. 1994;88(2):S5–S6.
   PubMedGoogle Scholar
• Kumari M, Chandra S, Tiwari N, et al. High throughput virtual screening to identify novel natural product inhibitors for methionyltRNA-synthetase of brucella melitensis. Bioinformation. 2017;13(1):8–16.
   PubMed Web of Science ®Google Scholar
• Dilek E, Erol HS, Cakir A, et al. Natural product inhibitors of carbonic anhydrase I and II isoenzymes: osajin and pomiferin. Arch Physiol Biochem. 2017;123(4):219–224.
   PubMed Web of Science ®Google Scholar
• Scotti L, Mendonça Júnior FJ, Ribeiro FF, et al. Natural product inhibitors of topoisomerases: review and docking study. Curr Protein Pept Sci. 2017;19(3):275–291.
   Web of Science ®Google Scholar
• Hielschermichael S, Griehl C, Buchholz M, et al. Natural products from microalgae with potential against Alzheimer’s disease: sulfolipids are potent glutaminyl cyclase inhibitors. Mar Drugs. 2016;14(11):203.
   Web of Science ®Google Scholar